0
Abstract: Poster Presentations |

THE TIME HAS COME FOR NEW, MORE PRECISE GUIDELINES IN THE TREATMENT OF HIGH RISK ACUTE CORONARY SYNDROMES WITH HEPARIN FREE TO VIEW

Zuzana Motovska, MD, PhD*; Petr Widimsky, MD; Robert Petr, MD; Andrea Andrasova, MD; Dana Bilkova, MD
Author and Funding Information

Third Faculty of Medicine, Charles University, Prague, Czech Republic


Chest


Chest. 2007;132(4_MeetingAbstracts):545. doi:10.1378/chest.132.4_MeetingAbstracts.545
Text Size: A A A
Published online

Abstract

PURPOSE: Antithrombin therapy with heparin is the evidence-based standard treatment in patients with NSTE ACS. UFH is to be preferred in high-risk NSTE-ACS patients with planned invasive strategy. The most vulnerable part of its application is correct dosing. The aim of this analysis was to define the risk factors which are associated with the problematic dose titration of UFH in high risk NSTE ACS patients.

METHODS: We analysed a group of 267 patients with high risk NSTE ACS managed with an early (≤;48h) invasive strategy and treated with the recommended dose of UFH (a bolus of 60–80 U/kg and an initial infusion of 12–15 U/kg per hour). The subsequent dose was adjusted after measurement of aPTT, using the nomogram. The goal for activated partial thromboplastin time was 45–70 seconds.

RESULTS: 29% of patients had a therapeutic initial aPTT value (6h after starting therapy). Half of them were overcoagulated, and 22% of patients were undertreated. By continuing therapy, the proportion of optimally treated patients increased. 40% of patients reached the therapeutic dose after 12 hours of treatment, and 58% after one day. Undertreatment is a problem in ≤;65-year old men. Women and older patients have a higher risk of overdose(fig). The patients with a therapeutic dose of UFH had the lowest occurrence of combined clinical end-point death and/or re-catheterization(5%). The highest occurrence of these events were in undertreated patients(7,2%). Overcoagulated patients had the highest rate of hemorrhage(10%). Renal function per se did not influence the anticoagulation activity of UFH. We discovered a correlation between renal function and loss of haemoglobin in patients treated with a full dose of UFH (r=0,212;p=0,019; R2–0,448)(fig).

CONCLUSION: The recommended weight adjusted first dose of UFH led to an optimal antithrombin effect in less then one third of high risk patients.

CLINICAL IMPLICATIONS: An expert consensus on more precise dose guidelines for UFH is needed. The dose of UFH can be not only weight, but also age and sex adjusted.

DISCLOSURE: Zuzana Motovska, No Financial Disclosure Information; No Product/Research Disclosure Information

Wednesday, October 24, 2007

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
Intraoperative Interventions*: American College of Chest Physicians Guidelines for the Prevention and Management of Postoperative Atrial Fibrillation After Cardiac Surgery
Antithrombotic Therapy for Non–ST-Segment Elevation Acute Coronary Syndromes*: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
New Antithrombotic Drugs*: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)*
PubMed Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543